Xin Ming, PhD

Xin Ming, PhD
Research Interests
- Drug and Gene Delivery
- Nanotechnology
- Cancer Immunotherapy
- Bioconjugation
- Cancer Targeted Delivery
- Education
- BS, 1998
- MS, 2001
- MS, 2001
- PhD, University of North Carolina, Chapel Hill, 2008
- Departments and Affiliations
- Center for Redox Biology and Medicine (CRBM)
- Comprehensive Cancer Center (CCC)
Research
- Delivery of an ectonucleotidase inhibitor with ROS-responsive nanoparticles overcomes adenosine-mediated cancer immunosuppression. Mao C, Yeh S, Fu J, Porosnicu M, Thomas A, Kucera GL, Votanopoulos KI, Tian S, Ming X. Sci Transl Med. 2022 Jun; 14(648):eabh1261.
- Elimination of acquired resistance to PD-1 blockade via the concurrent depletion of tumour cells and immunosuppressive cells. Xue G, Wang Z, Zheng N, Fang J, Mao C, Li X, Jin G, Ming X, Lu Y. Nat Biomed Eng. 2021 Nov; 5(11):1306-1319.
- P-glycoprotein-targeted photodynamic therapy boosts cancer nanomedicine by priming tumor microenvironment. Mao C, Li F, Zhao Y, Debinski W, Ming X. Theranostics. 2018; 8(22):6274-6290.
- P-glycoprotein targeted photodynamic therapy of chemoresistant tumors using recombinant Fab fragment conjugates. Mao C, Qu P, Miley MJ, Zhao Y, Li Z, Ming X. Biomater Sci. 2018 Oct; 6(11):3063-3074.
- P-Glycoprotein-Targeted Photothermal Therapy of Drug-Resistant Cancer Cells Using Antibody-Conjugated Carbon Nanotubes. Suo X, Eldridge BN, Zhang H, Mao C, Min Y, Sun Y, Singh R, Ming X. ACS Appl Mater Interfaces. 2018 Oct; 10(39):33464-33473.